Abbott shares drop after weak 2026 outlook and slowdown in nutrition, diabetes and diagnostics units

Thu, 16 Apr 2026 22:35:00 +0200

Abbott Laboratories shares fell roughly 6% after the company released its first‑quarter results and 2026 outlook, which disappointed many analysts on Wall Street. The medical‑device and nutrition giant flagged pressure across multiple business segments, including its nutrition products division and diabetes‑care devices, which saw softer sales than expected. Investors also reacted negatively to lighter revenue growth in diagnostics, where demand for flu and other viral tests declined versus the prior year. Meanwhile, Abbott’s heart‑device business has reportedly lost market share to rival Edwards Lifesciences in certain product categories, according to JPMorgan analyst Robbie Marcus. Overall, the combination of weaker end‑segment performance and cautious guidance pushed Abbott’s stock toward its lowest closing level since November 2023, marking one of its largest percentage declines in over a year and underscoring investor concerns about near‑term growth and margin pressures.